Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Angeles Wealth Management LLC

Angeles Wealth Management LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,047 shares of the pharmaceutical company’s stock after selling 67 shares during the period. Angeles Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $422,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in VRTX. Czech National Bank raised its stake in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after purchasing an additional 3,260 shares in the last quarter. Whalen Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the third quarter valued at about $662,000. Concord Wealth Partners raised its stake in Vertex Pharmaceuticals by 32.6% during the fourth quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock valued at $1,413,000 after buying an additional 862 shares in the last quarter. Mizuho Securities USA LLC lifted its holdings in Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock worth $35,994,000 after buying an additional 57,497 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Vertex Pharmaceuticals by 19.4% in the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock worth $137,783,000 after acquiring an additional 55,739 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several research analyst reports. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. lowered their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. Royal Bank of Canada raised their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $502.58.

Vertex Pharmaceuticals Trading Up 0.1 %

Shares of Vertex Pharmaceuticals stock opened at $469.97 on Tuesday. The business has a fifty day simple moving average of $435.87 and a 200-day simple moving average of $462.29. The firm has a market cap of $121.03 billion, a price-to-earnings ratio of -236.17, a price-to-earnings-growth ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.